Company intelligence / Profile preview

Tevera

Ownership: Private
Development stage: Commercial

Overview

Tevera has developed a rapid ex vivo diagnostic test using SMR technology to measure the growth response of live patient-derived tumor cells to various anti-cancer therapies. Early clinical results show approximately 80% predictive accuracy in guiding effective treatment choices for late-stage or relapsed cancer patients. Their LDTs are available for a wide range of cancers and therapies.

Therapeutic areas: Oncology
Modalities: Non-pharmacological therapy guidance (Laboratory Developed Test, LDT)Device-based diagnostic platform (Suspended Microchannel Resonator technology)
Industry: Protein Biomarker Diagnostics

Partnerships

Clinical collaborations with prominent U.S. academic medical institutions for ongoing studies

Beyond the preview

Go deeper on Tevera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tevera.

Explore the full profile